News Headlines Article

Amgen drug delayed spread of prostate cancer to bones, study finds
Los Angeles Times

The Amgen drug denosumab delayed the spread of prostate cancer to men’s bones, a company study found, sending shares of the Thousand Oaks firm higher Tuesday.

Use of the drug stalled the malignancy’s spread by 4.2 months, Amgen said. The study, part of the final phase of testing usually needed for U.S. approval, didn’t find a survival benefit.